UNLABELLED: Increased mitogen-activated protein kinase (MAPK) activity correlates with a more malignant hepatocellular carcinoma (HCC) phenotype. There is a reciprocal regulation between p44/42 MAPK (extracellular signal-regulated kinase [ERK]1/2) and the dual-specificity MAPK phosphatase MKP-1/DUSP1. ERK phosphorylates DUSP1, facilitating its proteasomal degradation, whereas DUSP1 inhibits ERK activity. Methionine adenosyltransferase 1a (Mat1a) knockout (KO) mice express hepatic S-adenosylmethionine (SAM) deficiency and increased ERK activity and develop HCC. The aim of this study was to examine whether DUSP1 expression is regulated by SAM and if so, elucidate the molecular mechanisms. Studies were conducted using Mat1a KO mice livers, cultured mouse and human hepatocytes, and 20S and 26S proteasomes. DUSP1 messenger RNA (mRNA) and protein levels were reduced markedly in livers of Mat1a KO mice and in cultured mouse and human hepatocytes with protein falling to lower levels than mRNA. SAM treatment protected against the fall in DUSP1 mRNA and protein levels in mouse and human hepatocytes. SAM increased DUSP1 transcription, p53 binding to DUSP1 promoter, and stability of its mRNA and protein. Proteasomal chymotrypsin-like and caspase-like activities were increased in Mat1a KO livers and cultured hepatocytes, which was blocked by SAM treatment. SAM inhibited chymotrypsin-like and caspase-like activities by 40% and 70%, respectively, in 20S proteasomes and caused rapid degradation of some of the 26S proteasomal subunits, which was blocked by the proteasome inhibitor MG132. SAM treatment in Mat1a KO mice for 7 days raised SAM, DUSP1, mRNA and protein levels and lowered proteosomal and ERK activities. CONCLUSION: DUSP1 mRNA and protein levels are lower in Mat1a KO livers and fall rapidly in cultured hepatocytes. SAM treatment increases DUSP1 expression through multiple mechanisms, and this may suppress ERK activity and malignant degeneration.
UNLABELLED: Increased mitogen-activated protein kinase (MAPK) activity correlates with a more malignant hepatocellular carcinoma (HCC) phenotype. There is a reciprocal regulation between p44/42 MAPK (extracellular signal-regulated kinase [ERK]1/2) and the dual-specificity MAPK phosphatase MKP-1/DUSP1. ERK phosphorylates DUSP1, facilitating its proteasomal degradation, whereas DUSP1 inhibits ERK activity. Methionine adenosyltransferase 1a (Mat1a) knockout (KO) mice express hepatic S-adenosylmethionine (SAM) deficiency and increased ERK activity and develop HCC. The aim of this study was to examine whether DUSP1 expression is regulated by SAM and if so, elucidate the molecular mechanisms. Studies were conducted using Mat1a KO mice livers, cultured mouse and human hepatocytes, and 20S and 26S proteasomes. DUSP1 messenger RNA (mRNA) and protein levels were reduced markedly in livers of Mat1a KO mice and in cultured mouse and human hepatocytes with protein falling to lower levels than mRNA. SAM treatment protected against the fall in DUSP1 mRNA and protein levels in mouse and human hepatocytes. SAM increased DUSP1 transcription, p53 binding to DUSP1 promoter, and stability of its mRNA and protein. Proteasomal chymotrypsin-like and caspase-like activities were increased in Mat1a KO livers and cultured hepatocytes, which was blocked by SAM treatment. SAM inhibited chymotrypsin-like and caspase-like activities by 40% and 70%, respectively, in 20S proteasomes and caused rapid degradation of some of the 26S proteasomal subunits, which was blocked by the proteasome inhibitor MG132. SAM treatment in Mat1a KO mice for 7 days raised SAM, DUSP1, mRNA and protein levels and lowered proteosomal and ERK activities. CONCLUSION:DUSP1 mRNA and protein levels are lower in Mat1a KO livers and fall rapidly in cultured hepatocytes. SAM treatment increases DUSP1 expression through multiple mechanisms, and this may suppress ERK activity and malignant degeneration.
Authors: S C Lu; L Alvarez; Z Z Huang; L Chen; W An; F J Corrales; M A Avila; G Kanel; J M Mato Journal: Proc Natl Acad Sci U S A Date: 2001-04-24 Impact factor: 11.205
Authors: Roland Hjerpe; Fabienne Aillet; Fernando Lopitz-Otsoa; Valerie Lang; Patrick England; Manuel S Rodriguez Journal: EMBO Rep Date: 2009-10-02 Impact factor: 8.807
Authors: Elena R García-Trevijano; María L Martínez-Chantar; M Ujue Latasa; José M Mato; Matías A Avila Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: Shelly C Lu; Komal Ramani; Xiaopeng Ou; Mark Lin; Victor Yu; Kwangsuk Ko; Ryan Park; Teodoro Bottiglieri; Hidekazu Tsukamoto; Gary Kanel; Samuel W French; José M Mato; Rex Moats; Edward Grant Journal: Hepatology Date: 2009-08 Impact factor: 17.425
Authors: Maria Lauda Tomasi; Ainhoa Iglesias-Ara; Heping Yang; Komal Ramani; Francesco Feo; Maria Rosa Pascale; M Luz Martínez-Chantar; José M Mato; Shelly C Lu Journal: Gastroenterology Date: 2008-09-25 Impact factor: 22.682
Authors: Maria L Martínez-Chantar; Fernando J Corrales; L Alfonso Martínez-Cruz; Elena R García-Trevijano; Zong-Zhi Huang; Lixin Chen; Gary Kanel; Matías A Avila; José M Mato; Shelly C Lu Journal: FASEB J Date: 2002-06-07 Impact factor: 5.191
Authors: Maria Lauda Tomasi; Ivan Tomasi; Komal Ramani; Rosa Maria Pascale; Jun Xu; Pasquale Giordano; José M Mato; Shelly C Lu Journal: Hepatology Date: 2012-07-12 Impact factor: 17.425
Authors: Ainara Cano; Xabier Buqué; Maite Martínez-Uña; Igor Aurrekoetxea; Ariane Menor; Juan L García-Rodríguez; Shelly C Lu; M Luz Martínez-Chantar; José M Mato; Begoña Ochoa; Patricia Aspichueta Journal: Hepatology Date: 2011-12 Impact factor: 17.425
Authors: Komal Ramani; Aaron E Robinson; Joshua Berlind; Wei Fan; Aushinie Abeynayake; Aleksandra Binek; Lucía Barbier-Torres; Mazen Noureddin; Nicholas N Nissen; Zehra Yildirim; Ebru Erbay; José M Mato; Jennifer E Van Eyk; Shelly C Lu Journal: Hepatology Date: 2021-12-18 Impact factor: 17.425